Published in
American Society for Microbiology, Antimicrobial Agents and Chemotherapy, 2(66), 2022
DOI: 10.1128/aac.02107-21
Links
Tools
Early Use of Sarilumab in Patients Hospitalized with COVID-19 Pneumonia and Features of Systemic Inflammation: the SARICOR Randomized Clinical Trial
Journal article published in 2022 by
Nicolás Merchante 
,
Sheila Cárcel,
José Carlos Garrido-Gracia,
Marta Trigo-Rodríguez,
María Ángeles Esteban Moreno,
Rafael León-López,
Reinaldo Espíndola-Gómez,
Eduardo Aguilar Alonso,
David Vinuesa García,
Alberto Romero-Palacios,
Inés Pérez-Camacho,
Belén Gutiérrez-Gutiérrez ,
Francisco Javier Martínez-Marcos,
Concepción Fernández-Roldán,
Pedro María Martínez Pérez-Crespo
and other authors.
,
Sheila Cárcel,
José Carlos Garrido-Gracia,
Marta Trigo-Rodríguez,
María Ángeles Esteban Moreno,
Rafael León-López,
Reinaldo Espíndola-Gómez,
Eduardo Aguilar Alonso,
David Vinuesa García,
Alberto Romero-Palacios,
Inés Pérez-Camacho,
Belén Gutiérrez-Gutiérrez ,
Francisco Javier Martínez-Marcos,
Concepción Fernández-Roldán,
Pedro María Martínez Pérez-Crespo
and other authors.
This paper is made freely available by the publisher.
Full text: Download
Data provided by 
Abstract
The objective of this study was to investigate the efficacy and safety of early treatment with sarilumab, added to standard of care (SOC), in hospitalized adults with COVID-19. Methods included phase II, open-label, randomized, controlled clinical trial of hospitalized patients with COVID-19 pneumonia and interleukin (IL)-6 levels ≥ 40 pg/mL and/or d-dimer > 1,500 ng/mL.